Personalis at 2021 Neoantigen Based Therapies Summit US: OCT 26-28, 2021
Presentation
Christelle Johnson, PhD
Senior Field Application Scientist
Cancer Genomics & Immuno-Oncology
Personalis, Inc.
OCT 26-28
ImmunoID NeXT: A Comprehensive Platform for Immuno-Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics, and Immunogenomics Profiling
- Accurate assessment of mutational landscape and putative neoantigens from the analytically-validated exome and transcriptome ImmunoID NeXT platform
- Improved neoantigen presentation and binding predictions through a machine learning algorithm, SHERPA, built upon high quality immunopeptidomics training data from mono-allelic, and multi-allelic samples
- Comprehensive immunogenomics profiling from a single sample to guide neoantigen-based therapies and biomarker discovery
